Monday, June 21, 2010

Piribo: New Publication Announcement, The Pharmaceutical Market: Israel

Piribo: New Publication Announcement, The Pharmaceutical Market: Israel

Piribo, (piribo. com) the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report called “The Pharmaceutical Market: Israel”.

(PRWEB) August 21, 2006

Israel's healthcare sector remains amid a period of uncertainty. The continuing political instability has been a significant factor in this malaise; healthcare policy has changed frequently and often faced widespread opposition. Progress within the sector is unlikely in the short term while government efforts are concentrated around the current dark state of Israeli-Palestine affairs.

The Israeli pharmaceutical market grew strongly in the 1990s, averaging around 10% per annum. Whether this level of growth continues, however, remains to be seen. Recent industry activity has been dominated by new legislation regarding drug pricing and parallel imports. After years of debate and delay new pricing regulations were implemented in June 2001, while legislation permitting the parallel trade of drugs was introduced in September 2000. Both reforms successfully overcame strong multinational opposition in the Supreme Court. This move marks a significant change in the relationship between multinationals and the regulatory authorities; traditionally the latter acted with the consent of the former with regard to major issues. In 2004, per capita expenditure on drugs in Israel stood in excess of US$230, the highest level in the Middle East.

Fluctuations in healthcare budgets, where heavy cutbacks were reversed by the government in the face of widespread opposition by many industry professionals in 2003, have caused additional concern over the future of national healthcare after 2002 saw the first ever decrease of healthcare spending in local currency terms since 1998. Allocations for the health basket are seemingly in a constant state of uncertainty. On a more positive note, the pharmaceutical giant Teva continues to record impressive financial growth and has emerged as a key player in the Israeli economy. In addition, the country continues to enhance its burgeoning reputation in the field of biotechnology, and possesses first class research and development facilities.

These pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

Contents

Background Data

Geography

Political Overview

Economic Overview

Population

Demographic Indicators

Mortality

Morbidity

Hiv/Aids

Charts

Organisation & Administration

Health Expenditure

Hospital Services

Ambulatory Care

Medical Personnel

Accessing The Pharmaceutical Market

Introduction

Regulatory Environment

Distribution Channels

Domestic Production

“The Pharmaceutical Market: Israel” is available from Piribo. For more information go to: http://www. piribo. com/publications/temp/pharmaceutical_market_israel. html (http://www. piribo. com/publications/temp/pharmaceutical_market_israel. html)

Piribo Product ID: ESP952

About Piribo.

Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.

###